RankAlpha logo
Back to Rankings

EVO

Evotec SEB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The base CRO/CDMO business is showing improving customer engagement, D&PD ex-strategic-partnership net sales growth, and high JEB utilization. Delayed partnership revenue is described as timing-related rather than lost, while Horizon targets approximately €75 million of annual run-rate savings by the end of 2027 [#PR-2026-07-13].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
D&PD and Just–Evotec Biologics revenues both declined year over year in preliminary Q2 and H1 results.
Momentum
98
Value
41
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.15 · Bull $3.25 · Bear $1.25
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-16 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $3.01
Why
Momentum98 · Δ7d -
Value41 · Δ7d -0.1
Sentiment51 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
98
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
51
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade B. Momentum 98.3 / Value 41.1 / Sentiment 50.8

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$696.22M
Beta
1.81
Shares Out
355.24M
P/E (TTM) · Derived
-6.0
P/S (TTM)
1.30
P/FCF (TTM) · Derived
-14.52
Rev YoY
-12.9%
EPS YoY
+329.2%
Gross Margin
+11.5%
Op Margin
-11.3%
Net Debt
-$33.71M
Current Ratio
1.68
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology